Neurolief

Neurolief develops treatments for patients with chronic neurological and neuropsychiatric disorders. The company has created a digital therapeutics platform of clinically proven neuromodulation-based solutions that can be delivered to patients at home or in the community. Neuroliefs Relivion is a noninvasive multichannel brain neuromodulation system for treating neurological and neuropsychiatric disorders. It offers precise, personalized care by delivering stimulation to six branches of the occipital and trigeminal nerves via three adaptive output channels. This creates a cumulative effect by releasing neurotransmitters in the brainstem to modulate the brain networks associated with pain and mood control. The Relivion device is placed comfortably on the patients head, where it stimulates the nerves. The connected e-Relief mobile app displays the treatment status and transmits information between the patient and the cloud. The Relivion system is FDA approved and CE marked and has been granted breakthrough device designation by the FDA.

Neurolief has raised $10.3M in total funding across 3 rounds. The company is currently at the A stage. Key investors include Brainsway, Undisclosed Investor(s), Terra Venture Partners.

Neurolief was founded in 2013 by Amit Dar (Co-founder & CTO).

Neurolief operates in Health Tech & Life Sciences, Digital Healthcare, Digital Therapeutics, with core technologies in Data Storage, Cloud, Artificial Intelligence. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Healthcare, Patients, Providers.

Neurolief is based in Sderot Giborei Israel 12, Netanya, Israel, Center District. The company also has offices abroad.